The Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each ....

Profit growth above 25%Revenue growth above 20%Exceptional itemEBITDA margin expansionResults View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹2462.00

prior close

₹2425.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.1%-3.5% vs market

Pharmaceuticals peers, median of 161sector+0.1%-3.7% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+2.0

15m

+1.6

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-0.1-3.5+0.1-3.7

Next day

-8.9-1.2-7.7+0.2-9.1

-8.6-3.7-4.9-1.4-7.2

-9.8-3.1-6.7-1.9-7.9

-8.5-2.0-6.6-1.6-7.0

-7.2-2.4-4.8-1.7-5.6

-6.9-1.9-5.0-2.0-4.9

15d

-8.4-2.4-6.1-0.7-7.8

-8.7-3.9-4.8-1.5-7.2

-0.2-1.2+1.0+3.4-3.6

-6.6+2.9-9.5+5.9-12.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin Ltd reported strong FY2026 results with standalone revenue growing 15% to Rs. 195.1 billion and consolidated revenue rising 23% to Rs. 279.6 billion year-on-year. Standalone net profit surged 60% to Rs. 63.7 billion while consolidated net profit increased 62% to Rs. 53.6 billion. EPS (basic, consolidated, after exceptional items) improved from Rs. 71.95 to Rs. 116.75. The Board recommended a dividend of Rs. 18 per share (900% of face value). Key exceptional items include antitrust litigation provisions of Rs. 5.8 billion, Astellas settlement costs of Rs. 8.5 billion, gains from divestments of Rs. 6.6 billion, and new labour code implementation costs of Rs. 512 million. The company completed acquisitions of VISUfarma B.V. and Renascience Pharma Limited. Cash flow from operations was strong at Rs. 73.3 billion on consolidated basis. Auditors B S R & Co. LLP gave an unmodified (clean) opinion.

Likely market impact

Lupin delivered robust profit growth exceeding 60% with healthy operating cash flows, signaling strong business recovery. The clean audit opinion removes concerns about financial reporting quality. However, shareholders should note ongoing antitrust litigation provisions and settlement costs represent contingent risks.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹7,475 Cr	₹5,667 Cr	+31.9%
Operating profit	₹1,919 Cr	₹838.9 Cr	+128.7%
Profit after tax	₹1,469 Cr	₹782.4 Cr	+87.7%
EBITDA margin	31.5%	23.3%	+8.2 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.